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INTRODUCTION
The advent of highly active antiretroviral therapy (HAART)
has substantially improved the prognosis of human immun-
odeficiency virus (HIV)-positive patients by reducing the
incidence of opportunistic infections and HIV-related mor-
tality (1). However, success rates outside clinical trial settings
are limited by treatment failure due to medication non-adher-
ence, drug toxicities, lack of drug potency and drug resis-
tance (2). The use of low-dose ritonavir (RTV) as a pharma-
cokinetic enhancer of other protease inhibitors (PIs) has
changed the management of HIV infection (3). Recently,
triple PI regimens, including the combination of two active
PIs with ritonavir as an enhancing agent, have been exam-
ined in treatment-experienced patients (4). 
Although prospective comparative trials of single RTV-
boosted PIs versus double-boosted PI combinations (e.g.,
lopinavir and ritonavir plus atazanavir) are lacking, the com-
binations of atazanavir (ATV), lopinavir/ritonavir (LPV/RTV),
and NRTIs has been shown to be effective in antiretroviral-
experienced and antiretroviral-naive patients (4-6). In Korea,
there are limited available treatment options because new
agents such as enfuvirtide (T-20), tenofovir, darunavir (TMC-
114), tipranavir and fosamprenavir are not available.
This report describes the use of double-boosted PI regimens
to achieve virological suppression in HIV-positive patients
who have a long history of virological failure in response to
treatment with antiretroviral drugs. 
CASE REPORT 
Case 1
A 34-yr-old male presented as HIV-positive in 1999. His
baseline CD4 cell count was 321 cells/μ L and his viral load
was 336,281 copies/mL. 
The patient was treated for four months with lamivudine,
zidovudine and indinavir starting in April 2001, but he vol-
untarily stopped the medication. He was admitted to the
hospital because of perianal infection and syphilis in Novem-
ber 2003. His viral load was 765,000 copies/mL and his
CD4 cell count was 2 cells/μ L at that time. He was started
on lamivudine, didanosine and indinavir with PCP/INH
prophylaxis. In March 2004, his drug regimen was changed
to lamivudine, stavudine and LPV/RTV because of nausea.
In August 2004, his viral load was 255,000 copies/mL and
we performed a drug resistance test to make a rational choice
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The combination of atazanavir (ATV) and lopinavir/ritonavir (LPV/RTV) with nucle-
oside reverse transcriptase inhibitors (NRTI) has been used as a salvage regimen
for human immunodeficiency virus (HIV)-positive patients. In this paper, we dis-
cuss two cases of HIV-positive patients who had long histories of virological failure
following a heavy treatment of antiretroviral drugs, but then achieved virological
suppression with double-boosted protease inhibitor (PI) regimens. In patients with
multiple genotypic resistance to PIs and NRTIs, virological suppression can be
achieved with a combination of ATV plus LPV/RTV with an NRTI backbone. The
two cases in this report suggest that a combination of ATV plus LPV/RTV could be
a useful salvage regimen for the subset of HIV-positive patients with limited treat-
ment options. 
Key Words : Double-Boosted Protease Inhibitor Therapy; Atazanavir; Lopinavir; Salvage Therapy; HIV Infec-
tions
Received : 23 July 2007
Accepted : 10 November 2007
. .738 H. Choi, S.J. Jeong, H.S. Lee, et al.
for rescue therapy. 
We performed viral genotypic resistance testing using
polymerase chain reaction (PCR) amplification conditions
based on the Stanford Center for AIDS Research laboratory
protocol for sequencing protease and reverse transcriptase
genes. Antiretroviral resistance interpretation was performed
using the HIV Drug Resistance Database of Stanford Uni-
versity (http://hivdb.stanford.edu).
Genotypic resistance analysis showed that the virus was
susceptible to all non-nucleoside reverse transcriptase inhi-
bitors (NNRTI) and resistant to all PIs and nucleoside reverse
transcriptase inhibitors (NRTI), except for zidovudine, stavu-
dine and tenofovir. Genotypic analysis showed resistance-
associated mutations both in the HIV reverse transcriptase
gene (L74V, M184V, V35I, K122E, D123N, I135L, S162C,
E194K, G196E, T200I, A272P, A288G, I293V, E297A,
and E300D) and in the protease gene (M46I, I154V, V82A,
L10V, L63A, and I15V). Based on these results, we changed
the regimen to zidovudine, didanosine and efavirenz in Novem-
ber 2004. One month later, we changed zidovudine to lamivu-
dine because of nausea. The patient then began LPV/RTV
in March 2005. One year after beginning the LPV/RTV reg-
imen, the patient’s CD4 cell count was 181 cells/μ L and his
viral load was 289,000 copies/mL. Finally, a new regimen of
lamivudine (150 mg twice daily), LPV/RTV (two tablets
twice daily), atazanavir (300 mg/day) and abacavir (600 mg/
day) resulted in virological success. The patient’s CD4 cell
count was 362/μ L and his viral load was 41.5 copies/mL
after six months of the new drug regimen. One year later,
his CD4 count increased to 534/μ L and virus was no longer
detected.   
Case 2
A 27-yr-old male patient presented with HIV infection
in December 1998. His baseline CD4 count was 190 cells/
μ L and his viral load was 135,894 copies/mL. He was treat-
ed by HAART with zidovudine, lamivudine and indinavir
for three years. In April 2002, he had suspected virological
failure and poor adherence so the indinavir was replaced with
efavirenz. Then, after the patient developed a rash, the efa-
virenz was replaced with kaletra. 
In September 2005, the patient was suspected to have viro-
logical failure and a genotypic resistance test was perform-
ed. The test showed mutations in the PI gene (L33F, M46I,
I54V, V82A, L10V, I13V, K14R, I15V, K55R, R57K, Q58E,
Q61H, I64V, and L76V) and in the RT gene (M41L, M184V,
T215Y, T7R, K11R, K30R, D123E, I135T, G196E, F214L,
D237N, V245T, R284K, A288S, I293V, and E300D). Geno-
typic resistance analysis showed that the virus was suscepti-
ble to all NNRTIs, and resistant to NRTIs and PIs. Based
on this result, we changed his regimen to didanosine, aba-
cavir and efavirenz in January 2006. In June 2006, he was
diagnosed with Tbc lymphadenitis and he received treatment
with an antituberculosis agent. At that time, his CD4 count
was 169 cells/μ L and his viral load was 60,000 copies/mL.
In October 2006, we changed his regimen to didanosine (400
mg/day), abacavir (600 mg/day), lamivudine (300 mg/day),
atazanavir (300 mg/day) and LPV/RTV (2 tablets twice daily)
due to virological failure. Six months later, his CD4 count
was 204 cells/μ L and his viral load was less than 40 copies/mL. 
DISCUSSION 
Ritonavir is a potent PI, but when prescribed at its rec-
ommended dose of 600 mg twice daily, it is not generally
well-tolerated due to its adverse effects. When utilized in a
low sub-therapeutic dose (100 or 200 mg), it acts as a phar-
macoenhancer of indinavir, amprenavir, saquinavir, lopinavir,
atazanavir and to a more limited extent, nelfinavir (7). Dou-
ble-boosting, also referred to as a triple PI combination, is a
term that describes the simultaneous use of two PIs with
low-dose ritonavir (8). 
Clinically, double-boosted PIs may serve multiple purpos-
es: 1) salvage therapy for highly antiretroviral-experienced
patients with limited treatment options due to extensive
reverse transcriptase (RT) resistance and protease resistance
(PR); 2) therapy for patients with retained PI activity, but
limited RT inhibitor options because of toxicities or resis-
tance; 3) initial therapy alone, thereby avoiding the potential
mitochondrial toxicities of NRTIs or; 4) initial therapy alone,
thereby avoiding agents with a low threshold to resistance,
such as lamivudine, emtricitabine and the NNRTIs (6). 
When RTV is used as a pharmacoenhancer, it increases
the drug levels of the boosted drug that it is combined with
in two ways: 1) inhibition of CYP3A4 in the gut wall and
liver and 2) possible inhibition of p-glycoprotein preventing
cellular drug efflux (5). The fixed combination of LPV and
low-dose RTV (Kaletra) facilitates the simultaneous boost-
ing of an additional PI. 
However, the interaction between the various PIs is not as
well characterized as the effect of ritonavir on the pharma-
cokinetics of PIs. Therefore, complex and unexpected inter-
actions can occur and therapeutic drug monitoring is neces-
sary to direct dosing and therapy. Administration of two PIs
boosted with low RTV doses can produce complex drug inter-
actions with unexpected results. Pharmacokinetic studies
are required to ensure that therapeutic drug concentrations
are being achieved in the plasma. A huge decrease in the
concentration of both PIs has been described when LPV/RTV
is administered with amprenavir or fosamprenavir (9-13).
This unfavorable reaction does not occur when LPV/RTV is
administered with saquinavir or when saquinavir and RTV
are administered with ATV (14-17). 
ATV appears to be a viable candidate to combine with
LPV/RTV in double-PI regimens because of its low daily
pill burden, modest CYP3A4 inhibition, different resistanceAtazanavir and Lopinavir/Ritonavir Combination Therapy  739
profiles and limited effects on lipid profiles. In a pharmacoki-
netic study, the combination of ATV and LPV/RTV provid-
ed high plasma concentrations of both PIs and was well tol-
erated despite the high plasma concentrations of both ATV
and LPV (4). 
Additionally, there are some data from non-comparative
studies confirming the improved treatment outcomes from
combinational PI therapy. Gilliam et al. suggested that the
combination of ATV+LPV/RTV with an NRTI backbone
could be considered for patients with multi-class resistance
(extensive RT and PR mutations), including predicted phe-
notypic and/or genotypic resistance to ATV and/or LPV/
RTV. In this study, 11 of 14 (79%) patients with 6 or more
PR mutations achieved virological success. Multiple NRTI
mutations were noted in 13 of 14 patients with 6 or more
PR mutations. Despite predicted phenotypic resistance to
ATV (6 patients) and LPV/RTV (7 patients), virological suc-
cess was achieved in 4 of 6 (67%) and 4 of 7 (57%) patients,
respectively. None of patients had phenotypic resistance to
ATV and LPV/RTV simultaneously (6). 
For the two cases in this study, there were long histories
of virological failure and multiple genotypic and phenotypic
resistances to PIs and NRTIs. However, virological suppres-
sion was achieved with a combination of ATV+LPV/RTV
with an NRTI backbone. These cases support the hypothe-
sis that the combination of ATV+LPV/RTV with NRTIs is
tolerable and efficacious in PI-resistant patients.
Further studies are necessary to achieve clinical utility and
specific indications for double-boosted PI therapy as a sal-
vage therapy, especially in genotypic and phenotypic PI-
resistant patients. 
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